Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Firy Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.57 (market cap $5.07B), while Firy Inc. trades at $9.97 (market cap $159.51M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 31.8× Firy Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Firy Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | FIRY | |
|---|---|---|
Market Cap | $5.07B | $159.51M |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $12.45 |
52-Week Low | $20.06 | $2.28 |
Enterprise Value | $4.19B | $103.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
FIRY trades at $9.98, down 4.77% in the last 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth and a slight earnings beat, yet maintains negative net income margins and cash flow challenges. Recent news includes a legal victory awarding $719 million and a rebrand from Skillz Inc.
Outlook remains cautious due to persistent losses and cash burn, though the legal win provides a liquidity boost. Risks include high SG&A costs and competitive pressures, while analyst sentiment is mixed with a majority hold rating. Investors should weigh the potential from strategic shifts against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
